First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
暂无分享，去创建一个
R. Herrmann | H. Hawle | S. Dimitrijević | C. Sessa | A. Wicki | A. Tzankov | Vladimir Cmiljanović | M. Joerger | M. Stumm | R. Kristeleit | C. Hierro | A. Xyrafas | R. Ritschard | D. Hess | V. Hess | A. Childs | N. Brown | S. Berardi | V. Pretre | R. von Moos | J. Rodón | Nataša Cmiljanović | V. Bize